Medicare’s New GLP-1 Bridge Program: Expanded Access to Weight-Loss Medications
For many years, Medicare generally did not cover prescription medications used solely for weight loss. That changed on July 1, 2026, when the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge Program. This temporary demonstration program is designed to give eligible Medicare beneficiaries access to certain GLP-1 medications for weight management at a significantly reduced cost. The program is currently scheduled to continue through December 31, 2027.
Key Highlights of the Program
● Low monthly cost. Eligible beneficiaries pay a $50 monthly copayment for covered medications through the Bridge Program. (Centers for Medicare & Medicaid Services)
● Available nationwide. The program is available to eligible beneficiaries in all 50 states and U.S. territories. (Medicare)
● Current covered medications include:
-
Wegovy®
-
Zepbound® (KwikPen formulation only)
-
Foundayo® (Medicare)
Who is Eligible?
To be eligible, you must:
● Be enrolled in Medicare Part D, either through a standalone Prescription Drug Plan (PDP) or a Medicare Advantage Prescription Drug plan (MAPD).
● Meet Medicare’s clinical eligibility requirements for obesity or overweight with qualifying health conditions.
● Have your healthcare provider prescribe the medication and complete the required prior authorization.
● Be participating in, or agree to participate in a lifestyle program that includes nutrition, physical activity, and ongoing weight management support.
Additional Information
● This is a temporary demonstration program and is currently scheduled to end on December 31, 2027.
● The program operates outside of your Medicare Part D prescription drug plan, so the $50 copayment does not count toward your Part D deductible or out-of-pocket prescription drug costs (TrOOP). (Centers for Medicare & Medicaid Services).
● Individuals who already qualify for Medicare coverage of a GLP-1 medication for another approved medical condition, such as Type 2 diabetes, generally receive that coverage through their existing Medicare drug plan rather than through the Bridge Program. (Centers for Medicare & Medicaid Services).
● Because this is a CMS demonstration program, program rules and covered medications may change before the program ends on December 31, 2027.
Why This Matters
Until now, Medicare generally excluded coverage for medications prescribed solely for weight loss. The Bridge Program represents the first nationwide Medicare initiative specifically designed to improve access to newer GLP-1 medications for eligible beneficiaries with obesity. For many people, it may significantly reduce the cost of medications that were previously unaffordable.
Meeting the BMI requirements alone does not guarantee approval. Beneficiaries must also meet Medicare’s clinical criteria, and prior authorization is required before coverage is approved. .
If you think you may qualify, start by discussing your health history and treatment options with your physician. If your physician believes a GLP-1 medication may be appropriate, they can determine whether you meet Medicare’s clinical requirements and submit the necessary prior authorization. For additional information about the GLP-1 Bridge Program, visit Medicare.gov or call 1-800-MEDICARE. (Medicare) If you have any questions about how the program works with your Medicare prescription drug coverage, I’m happy to help explain your Medicare benefits and answer your Medicare-related questions.